Abstract
A series of novel 3-O-arylalkylbenzamide derivatives as FtsZ inhibitors was designed, synthesized and evaluated for their cell division inhibitory activity against B. subtilis and S. aureus, and in vitro antibacterial activity against various phenotypes of Gram-positive bacteria. This series showed significantly improved on-target activity and in vitro antibacterial activity compared with 3-MBA. Among them, 3-O-alkylbenzamids 4–8 and 3-O-bromoalkylbenzamides 9 and 10 showed significantly improved activity against three phenotypes of S. aureus ATCC25923, S. aureusATCC29213 (MRSA) and S. aureus PR. Preliminary structure-activity relationships indicated that the extension of 3-O-alkyl side chain resulted in a substantial improvement in the antibacterial activity, and the small group like methyl or ethyl group at the position 1–3 of the 3-O-alkyl side chain did not affect the antibacterial activity while the large group such as benzene or heterocycle at the position 4 or 5 of the 3-O-alkyl side chain could lead to poor antibacterial activity.
Keywords: Antibacterial evaluation, 3-O-Arylalkyl groups, Benzamide derivatives, FtsZ inhibitors, Resistant bacteria, Synthesis
Letters in Drug Design & Discovery
Title:The Synthesis and Antibacterial Activity of Novel 3-O-arylalkylbenzamide Derivatives as FtsZ Inhibitors
Volume: 10 Issue: 4
Author(s): Siti Ma, Rongmei Wang, Yuanze Wang, Jichao Cao and Shutao Ma
Affiliation:
Keywords: Antibacterial evaluation, 3-O-Arylalkyl groups, Benzamide derivatives, FtsZ inhibitors, Resistant bacteria, Synthesis
Abstract: A series of novel 3-O-arylalkylbenzamide derivatives as FtsZ inhibitors was designed, synthesized and evaluated for their cell division inhibitory activity against B. subtilis and S. aureus, and in vitro antibacterial activity against various phenotypes of Gram-positive bacteria. This series showed significantly improved on-target activity and in vitro antibacterial activity compared with 3-MBA. Among them, 3-O-alkylbenzamids 4–8 and 3-O-bromoalkylbenzamides 9 and 10 showed significantly improved activity against three phenotypes of S. aureus ATCC25923, S. aureusATCC29213 (MRSA) and S. aureus PR. Preliminary structure-activity relationships indicated that the extension of 3-O-alkyl side chain resulted in a substantial improvement in the antibacterial activity, and the small group like methyl or ethyl group at the position 1–3 of the 3-O-alkyl side chain did not affect the antibacterial activity while the large group such as benzene or heterocycle at the position 4 or 5 of the 3-O-alkyl side chain could lead to poor antibacterial activity.
Export Options
About this article
Cite this article as:
Ma Siti, Wang Rongmei, Wang Yuanze, Cao Jichao and Ma Shutao, The Synthesis and Antibacterial Activity of Novel 3-O-arylalkylbenzamide Derivatives as FtsZ Inhibitors, Letters in Drug Design & Discovery 2013; 10 (4) . https://dx.doi.org/10.2174/1570180811310040005
DOI https://dx.doi.org/10.2174/1570180811310040005 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Coumarin and Isocoumarin as Serine Protease Inhibitors
Current Pharmaceutical Design The Detection of Pb<sup>2+</sup> Using Glutathione Capped Mn Doped ZnS QDs
Current Analytical Chemistry Treatment of Tuberculosis in Nano Era: Recent Avenues
Current Bioactive Compounds COVID-19 and Brain Aging: What are the Implications of Immunosenescence?
Current Aging Science Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) High Resolution Magic Angle Spinning NMR for Analyzing Small Molecules Attached to Solid Support
Combinatorial Chemistry & High Throughput Screening Prodrug Design Targeting Intestinal PepT1 for Improved Oral Absorption: Design and Performance
Current Drug Metabolism Utility of Lung Ultrasound in Decision-making to Prioritize Hospital Admission for COVID-19 Patients: A Developing Country Perspective
Current Medical Imaging Redox Processes in Neurodegenerative Disease Involving Reactive Oxygen Species
Current Neuropharmacology COVID-19 Pandemic and the Impact on the Cardiovascular Disease Patient Care
Current Cardiology Reviews The Pictet-Spengler Reaction Still on Stage
Current Pharmaceutical Design Pathophysiology of Metastatic Bone Disease and the Role of the Second Generation of Bisphosphonates: From Basic Science to Medicine
Current Pharmaceutical Design The Use of Computational Methods in the Discovery and Design of Kinase Inhibitors
Current Pharmaceutical Design Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy
Current Pharmaceutical Design In Vivo Cellular Imaging for Translational Medical Research
Current Medical Imaging Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer
Mini-Reviews in Medicinal Chemistry Mapping of New Pharmacological Alternatives in the Face of the Emergence of Antibiotic Resistance in COVID-19 Patents Treated for Opportunistic Respiratory Bacterial Pathogens
Recent Advances in Anti-Infective Drug Discovery Pharmacophore Searching of Benzofuran Derivatives for Selective CYP19 Aromatase Inhibition
Letters in Drug Design & Discovery Radiomics and Diagnostic CT-MRI
Current Medical Imaging Favipiravir in SARS-CoV-2 Infection: Is it Worth it?
Combinatorial Chemistry & High Throughput Screening